GSK plc Sponsored ADR (GSK)
Bharat, GSK to halve price of malaria vaccine by 2028
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday.
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
Here's Why GSK (GSK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
GSK seeks broader European approval for RSV vaccine
GSK PLC (LSE:GSK, NYSE:GSK) has taken a step towards widening access to its respiratory syncytial virus (RSV) vaccine in Europe, with the European Medicines Agency accepting its application to expand the vaccine's use to all adults aged 18 and over. The vaccine, sold under the name Arexvy, is already authorised across Europe for adults aged 60 and over, as well as those aged 50 to 59 who are at increased risk due to underlying health conditions.
Here's Why GSK (GSK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
